136 related articles for article (PubMed ID: 8778929)
21. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
[TBL] [Abstract][Full Text] [Related]
22. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
23. [Positron emission tomography (PET) in diagnosis and therapy planning of malignant lymphoma].
Dimitrakopoulou-Strauss A; Strauss LG; Goldschmidt H; Hegenbart U; Irngartinger G; Oberdorfer F; van Kaick G
Radiologe; 1997 Jan; 37(1):74-80. PubMed ID: 9157479
[TBL] [Abstract][Full Text] [Related]
24. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem.
Kato T; Fukatsu H; Ito K; Tadokoro M; Ota T; Ikeda M; Isomura T; Ito S; Nishino M; Ishigaki T
Eur J Nucl Med; 1995 Jan; 22(1):32-9. PubMed ID: 7698152
[TBL] [Abstract][Full Text] [Related]
25. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: a prospective study.
Sperti C; Pasquali C; Decet G; Chierichetti F; Liessi G; Pedrazzoli S
J Gastrointest Surg; 2005 Jan; 9(1):22-8; discussion 28-9. PubMed ID: 15623441
[TBL] [Abstract][Full Text] [Related]
26. Preoperative evaluation of pancreatic masses with positron emission tomography using 18F-fluorodeoxyglucose: diagnostic limitations.
Sendler A; Avril N; Helmberger H; Stollfuss J; Weber W; Bengel F; Schwaiger M; Roder JD; Siewert JR
World J Surg; 2000 Sep; 24(9):1121-9. PubMed ID: 11036292
[TBL] [Abstract][Full Text] [Related]
27. Role and limitations of 18F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions.
Pery C; Meurette G; Ansquer C; Frampas E; Regenet N
Gastroenterol Clin Biol; 2010 Sep; 34(8-9):465-74. PubMed ID: 20688444
[TBL] [Abstract][Full Text] [Related]
28. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer.
Bang S; Chung HW; Park SW; Chung JB; Yun M; Lee JD; Song SY
J Clin Gastroenterol; 2006; 40(10):923-9. PubMed ID: 17063113
[TBL] [Abstract][Full Text] [Related]
29. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures.
Schirrmeister H; Kühn T; Guhlmann A; Santjohanser C; Hörster T; Nüssle K; Koretz K; Glatting G; Rieber A; Kreienberg R; Buck AC; Reske SN
Eur J Nucl Med; 2001 Mar; 28(3):351-8. PubMed ID: 11315604
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
31. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US.
Inokuma T; Tamaki N; Torizuka T; Magata Y; Fujii M; Yonekura Y; Kajiyama T; Ohshio G; Imamura M; Konishi J
Radiology; 1995 May; 195(2):345-52. PubMed ID: 7724751
[TBL] [Abstract][Full Text] [Related]
33. Ki-67 immunostaining in pancreatic cancer and chronic active pancreatitis: does in vivo FDG uptake correlate with proliferative activity?
Buck AC; Schirrmeister HH; Guhlmann CA; Diederichs CG; Shen C; Buchmann I; Kotzerke J; Birk D; Mattfeldt T; Reske SN
J Nucl Med; 2001 May; 42(5):721-5. PubMed ID: 11337566
[TBL] [Abstract][Full Text] [Related]
34. [Positron emission tomography in diagnosis of renal cell carcinoma].
Bachor R; Kotzerke J; Gottfried HW; Brändle E; Reske SN; Hautmann R
Urologe A; 1996 Mar; 35(2):146-50. PubMed ID: 8650849
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer.
Imdahl A; Nitzsche E; Krautmann F; Högerle S; Boos S; Einert A; Sontheimer J; Farthmann EH
Br J Surg; 1999 Feb; 86(2):194-9. PubMed ID: 10100786
[TBL] [Abstract][Full Text] [Related]
36. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer.
Rose DM; Delbeke D; Beauchamp RD; Chapman WC; Sandler MP; Sharp KW; Richards WO; Wright JK; Frexes ME; Pinson CW; Leach SD
Ann Surg; 1999 May; 229(5):729-37; discussion 737-8. PubMed ID: 10235532
[TBL] [Abstract][Full Text] [Related]
37. Nonfunctioning endocrine pancreatic tumor examined with 18F-FDG PET/CT.
Toshikuni N; Kai K; Fujisawa M
Ann Nucl Med; 2008 Feb; 22(2):133-7. PubMed ID: 18311538
[TBL] [Abstract][Full Text] [Related]
38. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
[TBL] [Abstract][Full Text] [Related]
39. Values and limitations of 18F-fluorodeoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses.
Diederichs CG; Staib L; Vogel J; Glasbrenner B; Glatting G; Brambs HJ; Beger HG; Reske SN
Pancreas; 2000 Mar; 20(2):109-16. PubMed ID: 10707924
[TBL] [Abstract][Full Text] [Related]
40. Is positron emission tomography using 18F-fluorodeoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses?
Rasmussen I; Sörensen J; Långström B; Haglund U
Scand J Surg; 2004; 93(3):191-7. PubMed ID: 15544073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]